Cytogenetic and molecular landscape and its potential clinical significance in Hispanic CMML patients from Puerto Rico

Jiang, Zeju; Sun, Xinlai; Wu, Zhan; Alhatem, Albert; Zheng, Ruifang; Liu, Dongfang; Wang, Yaqun; Kumar, Dibyendu; Xia, Chang-Qing; You, Bo; Wang, He; Liu, Chen; Jiang, Jie‐Gen

doi:10.18632/oncotarget.27824

Cited by 4 publications

(5 citation statements)

References 24 publications

(57 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thirty-five studies were used for the analysis of fibrinogen levels in both severe and non-severe groups 4 , 5 , 34 – 65 ( Table 1 ). Fibrinogen levels have been reported in 2207 severe patients with COVID-19 and 6057 non-severe patients with COVID-19.…”

Section: Resultsmentioning

confidence: 99%

Hemostatic System (Fibrinogen Level, D-Dimer, and FDP) in Severe and Non-Severe Patients With COVID-19: A Systematic Review and Meta-Analysis

Rostami

Khoshnegah

Mansouritorghabeh

2021

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

SARS-CoV-2 in COVID-19 triggers abnormalities in coagulation parameters that can contribute to thrombosis. The goals of this research were to determine the levels of fibrinogen, D-dimer and FDP in COVID-19 patients. Following a systematic study, among 1198 articles, 35 studies were included in the meta-analysis of fibrinogen levels in both severe and non-severe groups. The funnel plot, Egger’s regression asymmetry test, and Begg’s test used to measure the bias of publications. All meta-analysis performed by comprehensive meta-analysis version 2 (CMA2). The pooled findings of fibrinogen levels revealed a significant rise in fibrinogen levels in severe COVID-19 than non-severe patients with COVID-19. The D-dimer and FDP levels were significantly higher in severe patients than non-severe patients with COVID-19 were. The levels of fibrinogen, D-dimer, and FDP have increased significantly in ICU patients compared to non-ICU patients. Although, levels of clotting parameters do not always correlate with the severity of disease, these findings showed the diagnostic importance for fibrinogen, D-dimer, and FDP in COVID-19. The presence of a continuous rise in serial measurements of fibrinogen, D-dimer, and FDP may predict that patients with COVID-19 may become critically ill.

show abstract

Section: Resultsmentioning

confidence: 99%

Hemostatic System (Fibrinogen Level, D-Dimer, and FDP) in Severe and Non-Severe Patients With COVID-19: A Systematic Review and Meta-Analysis

Rostami

Khoshnegah

Mansouritorghabeh

2021

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

show abstract

“…Racial disparities of cytogenetic and molecular abnormalities could be an explanation for lower mortality rates among the Puerto Rican population when compared to other racial/ethnic groups. A study among Hispanics from Puerto Rico living in California, diagnosed from 2009 to 2018 with chronic myelomonocytic leukemia (CMML), found a higher rate of mutated TET2 and wild ASXL1 [ 22 ]. Mutated TET2 and wild ASXL1 are associated with a better prognosis of CMML.…”

Section: Discussionmentioning

confidence: 99%

“…Mutated TET2 and wild ASXL1 are associated with a better prognosis of CMML. However, the higher rates of mutated TET2 and wild ASXL1 among Hispanics in the same study may explain the unfavorable prognosis of AML in Hispanics [ 22 ]. Also, a recent study among USH in Texas demonstrated worse overall survival for Hispanic patients with AML and CML living in El Paso near the US/Mexico border compared to USH living elsewhere in Texas [ 23 ].…”

Section: Discussionmentioning

confidence: 99%

“…It is important to highlight that the differences observed in incidence and mortality of leukemia could be due to social and economic factors. Racial minorities have persistently discrimination which is associated with worse health outcomes and are exposed to more risk factors that the more advantaged social groups [ 21 , 22 ]. Access to care is vital for promoting the health of the population and achieving equity.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Racial/ethnic disparities for leukemias in Puerto Rico and the United States of America, 2015–2019

et al. 2023

View full text Add to dashboard Cite

Background Leukemia is a cancer of the early-forming cells. Over the past decade, leukemia racial/ethnic disparities have been documented in the United States of America (USA). Although the Puerto Rican population in the USA represents the second-largest Hispanic population in the nation, most of the existing studies do not include Puerto Rico. We compared the incidence and mortality rates for leukemia and its subtypes in Puerto Rico and four racial/ethnic groups in the USA. Methods We used data from the Puerto Rico Central Cancer Registry and the Surveillance, Epidemiology, and End Results Program (2015–2019). The racial/ethnic groups studied were non-Hispanic whites (NHW), non-Hispanic blacks (NHB), Hispanics (USH), and Asian/Pacific Islanders (NHAPI) living in the USA and the Puerto Rico population. We calculated the incidence and mortality rates. The relative risk of developing or dying due to leukemia was also calculated. Results Compared with Puerto Rico, NHW [standardized incidence rate (SIR) = 1.47; 95%CI = 1.40–1.53; standardized mortality rates (SMR) = 1.55; 95%CI = 1.45–1.65)] and NHB (SIR = 1.09; 95%CI = 1.04–1.15; SMR = 1.27; 95%CI = 1.19–1.35) had higher incidence and mortality rates; but lower than the NHAPI (SIR = 0.78; 95%CI = 0.74–0.82; SMR = 0.83; 95%CI = 0.77–0.89); and similar to USH. However, we found differences among leukemia subtypes. For example, NHAPI and USH had lower risk of developing chronic leukemias than Puerto Rico. We found a lower risk to develop acute lymphocytic leukemia in NHB than in Puerto Rico. Conclusions Our study provides a better understanding of leukemia’s racial/ethnic disparities and fills a knowledge gap by examining the incidence and mortality rates in Puerto Rico. Future studies are needed to better understand the factors influencing the differences found in the incidence and mortality of leukemia among different racial/ethnic groups.

show abstract

“…These include acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), myelodysplastic syndrome (MDS), and solid tumors, such as bladder cancer. Its expression is also associated with poor prognosis (Cristóbal et al, 2010; Eisfeld et al, 2020; Elena et al, 2016; Hwang et al, 2019; Jiang et al, 2020; Li et al, 2021; Lucas et al, 2018; Martín et al, 2020; Robinson et al, 2020; Tang et al, 2022). The major cause of elevated SETBP1 expression is mutations in and around the SKI region; however, there are also known cases that occur in the absence of SETBP1 mutations (discussed later).…”

Section: Setbp1 Mutations In Cancermentioning

confidence: 99%

The impact of SETBP1 mutations in neurological diseases and cancer

Kohyanagi,

Ohama

2023

Genes to Cells

View full text Add to dashboard Cite

SE translocation (SET) is a cancer‐promoting factor whose expression is upregulated in many cancers. High SET expression positively correlates with a poor cancer prognosis. SETBP1 (SET‐binding protein 1/SEB/MRD29), identified as SET‐binding protein, is the causative gene of Schinzel–Giedion syndrome, which is characterized by severe intellectual disability and a distorted facial appearance. Mutations in these genetic regions are also observed in some blood cancers, such as myelodysplastic syndromes, and are associated with a poor prognosis. However, the physiological role of SETBP1 and the molecular mechanisms by which the mutations lead to disease progression have not yet been fully elucidated. In this review, we will describe the current epidemiological data on SETBP1 mutations and shed light on the current knowledge about the SET‐dependent and ‐independent functions of SETBP1.

show abstract

Cytogenetic and molecular landscape and its potential clinical significance in Hispanic CMML patients from Puerto Rico

Cited by 4 publications

References 24 publications

Hemostatic System (Fibrinogen Level, D-Dimer, and FDP) in Severe and Non-Severe Patients With COVID-19: A Systematic Review and Meta-Analysis

Hemostatic System (Fibrinogen Level, D-Dimer, and FDP) in Severe and Non-Severe Patients With COVID-19: A Systematic Review and Meta-Analysis

Racial/ethnic disparities for leukemias in Puerto Rico and the United States of America, 2015–2019

The impact of SETBP1 mutations in neurological diseases and cancer

Contact Info

Product

Resources

About